Investor Relations

Print   Email  
Stock price graph

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. All of Tranzyme’s product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH™, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner.

View all »   RSSRecent Releases

May 10, 2012
Tranzyme Pharma Announces First Quarter 2012 Financial Results

May 3, 2012
Tranzyme Pharma to Report First Quarter 2012 Financial Results

Investors